FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3186991133> ?p ?o ?g. }

• W3186991133 endingPage "700" @default.
• W3186991133 startingPage "690" @default.
• W3186991133 abstract "ZUMA-1 (NCT02348216) examined the safety and efficacy of axicabtagene ciloleucel (axi-cel), an autologous CD19-directed chimaeric antigen receptor (CAR)-T cell therapy, in refractory large B-cell lymphoma. To reduce treatment-related toxicity, several exploratory safety management cohorts were added to ZUMA-1. Specifically, cohort 6 investigated management of cytokine release syndrome (CRS) and neurologic events (NEs) with prophylactic corticosteroids and earlier corticosteroid and tocilizumab intervention. CRS and NE incidence and severity were primary end-points. Following leukapheresis, patients could receive optional bridging therapy per investigator discretion. All patients received conditioning chemotherapy (days -5 through -3), 2 × 106 CAR-T cells/kg (day 0) and once-daily oral dexamethasone [10 mg, day 0 (before axi-cel) through day 2]. Forty patients received axi-cel. CRS occurred in 80% of patients (all grade ≤2). Any grade and grade 3 or higher NEs occurred in 58% and 13% of patients respectively. Sixty-eight per cent of patients did not experience CRS or NEs within 72 h of axi-cel. With a median follow-up of 8·9 months, objective and complete response rates were 95% and 80% respectively. Overall, prophylactic corticosteroids and earlier corticosteroid and/or tocilizumab intervention resulted in no grade 3 or higher CRS, a low rate of grade 3 or higher NEs and high response rates in this study population." @default.
• W3186991133 created "2021-08-02" @default.
• W3186991133 creator A5005241734 @default.
• W3186991133 creator A5005446802 @default.
• W3186991133 creator A5013177563 @default.
• W3186991133 creator A5015194203 @default.
• W3186991133 creator A5015845334 @default.
• W3186991133 creator A5029620109 @default.
• W3186991133 creator A5032917190 @default.
• W3186991133 creator A5033073385 @default.
• W3186991133 creator A5036293139 @default.
• W3186991133 creator A5037526878 @default.
• W3186991133 creator A5040504519 @default.
• W3186991133 creator A5043125083 @default.
• W3186991133 creator A5043341277 @default.
• W3186991133 creator A5049413660 @default.
• W3186991133 creator A5051092535 @default.
• W3186991133 creator A5066129729 @default.
• W3186991133 creator A5066618983 @default.
• W3186991133 creator A5068452218 @default.
• W3186991133 creator A5070180314 @default.
• W3186991133 creator A5074136068 @default.
• W3186991133 creator A5079582306 @default.
• W3186991133 creator A5079688295 @default.
• W3186991133 creator A5080373697 @default.
• W3186991133 creator A5081343057 @default.
• W3186991133 creator A5089882481 @default.
• W3186991133 creator A5090442154 @default.
• W3186991133 creator A5090694142 @default.
• W3186991133 date "2021-07-22" @default.
• W3186991133 modified "2023-10-11" @default.
• W3186991133 title "Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B‐cell lymphoma" @default.
• W3186991133 cites W1964475341 @default.
• W3186991133 cites W2031026757 @default.
• W3186991133 cites W2036193982 @default.
• W3186991133 cites W2082708772 @default.
• W3186991133 cites W2099570622 @default.
• W3186991133 cites W2107925822 @default.
• W3186991133 cites W2133201432 @default.
• W3186991133 cites W2150291618 @default.
• W3186991133 cites W2773804840 @default.
• W3186991133 cites W2808166290 @default.
• W3186991133 cites W2899385155 @default.
• W3186991133 cites W2903225254 @default.
• W3186991133 cites W2904964912 @default.
• W3186991133 cites W2917403768 @default.
• W3186991133 cites W2932076001 @default.
• W3186991133 cites W2942621614 @default.
• W3186991133 cites W2944998775 @default.
• W3186991133 cites W2949232578 @default.
• W3186991133 cites W2991566266 @default.
• W3186991133 cites W3004644443 @default.
• W3186991133 cites W3024978145 @default.
• W3186991133 cites W3047493249 @default.
• W3186991133 cites W3081041696 @default.
• W3186991133 cites W3092023747 @default.
• W3186991133 cites W3097517620 @default.
• W3186991133 cites W3097908464 @default.
• W3186991133 cites W3105850195 @default.
• W3186991133 cites W3128956257 @default.
• W3186991133 cites W4205736005 @default.
• W3186991133 doi "https://doi.org/10.1111/bjh.17527" @default.
• W3186991133 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8457222" @default.
• W3186991133 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34296427" @default.
• W3186991133 hasPublicationYear "2021" @default.
• W3186991133 type Work @default.
• W3186991133 sameAs 3186991133 @default.
• W3186991133 citedByCount "64" @default.
• W3186991133 countsByYear W31869911332021 @default.
• W3186991133 countsByYear W31869911332022 @default.
• W3186991133 countsByYear W31869911332023 @default.
• W3186991133 crossrefType "journal-article" @default.
• W3186991133 hasAuthorship W3186991133A5005241734 @default.
• W3186991133 hasAuthorship W3186991133A5005446802 @default.
• W3186991133 hasAuthorship W3186991133A5013177563 @default.
• W3186991133 hasAuthorship W3186991133A5015194203 @default.
• W3186991133 hasAuthorship W3186991133A5015845334 @default.
• W3186991133 hasAuthorship W3186991133A5029620109 @default.
• W3186991133 hasAuthorship W3186991133A5032917190 @default.
• W3186991133 hasAuthorship W3186991133A5033073385 @default.
• W3186991133 hasAuthorship W3186991133A5036293139 @default.
• W3186991133 hasAuthorship W3186991133A5037526878 @default.
• W3186991133 hasAuthorship W3186991133A5040504519 @default.
• W3186991133 hasAuthorship W3186991133A5043125083 @default.
• W3186991133 hasAuthorship W3186991133A5043341277 @default.
• W3186991133 hasAuthorship W3186991133A5049413660 @default.
• W3186991133 hasAuthorship W3186991133A5051092535 @default.
• W3186991133 hasAuthorship W3186991133A5066129729 @default.
• W3186991133 hasAuthorship W3186991133A5066618983 @default.
• W3186991133 hasAuthorship W3186991133A5068452218 @default.
• W3186991133 hasAuthorship W3186991133A5070180314 @default.
• W3186991133 hasAuthorship W3186991133A5074136068 @default.
• W3186991133 hasAuthorship W3186991133A5079582306 @default.
• W3186991133 hasAuthorship W3186991133A5079688295 @default.
• W3186991133 hasAuthorship W3186991133A5080373697 @default.
• W3186991133 hasAuthorship W3186991133A5081343057 @default.
• W3186991133 hasAuthorship W3186991133A5089882481 @default.
• W3186991133 hasAuthorship W3186991133A5090442154 @default.

• next